Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4193 entries
Sorted by: Best Match Show Resources per page
Fertility preservation during cancer treatment: clinical guidelines.

Cancer management and research

Rodriguez-Wallberg KA, Oktay K.
PMID: 24623991
Cancer Manag Res. 2014 Mar 04;6:105-17. doi: 10.2147/CMAR.S32380. eCollection 2014.

The majority of children, adolescents, and young adults diagnosed with cancer today will become long-term survivors. The threat to fertility that cancer treatments pose to young patients cannot be prevented in many cases, and thus research into methods for...

Cite
Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res. 2014;6:105-17doi: 10.2147/CMAR.S32380.
Rodriguez-Wallberg, K. A., & Oktay, K. (2014). Fertility preservation during cancer treatment: clinical guidelines. Cancer management and research, 6105-17. https://doi.org/10.2147/CMAR.S32380
Rodriguez-Wallberg, Kenny A, and Oktay, Kutluk. "Fertility preservation during cancer treatment: clinical guidelines." Cancer management and research vol. 6 (2014): 105-17. doi: https://doi.org/10.2147/CMAR.S32380
Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res. 2014 Mar 04;6:105-17. doi: 10.2147/CMAR.S32380. eCollection 2014. PMID: 24623991; PMCID: PMC3949560.
Copy Download .nbib Format: NLM
Head and neck cancer: improving outcomes with a multidisciplinary approach.

Cancer management and research

Lo Nigro C, Denaro N, Merlotti A, Merlano M.
PMID: 28860859
Cancer Manag Res. 2017 Aug 18;9:363-371. doi: 10.2147/CMAR.S115761. eCollection 2017.

For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard treatment. The multidisciplinary approach, which includes multimodality treatment with S followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy (CRT), is required...

Cite
Lo Nigro C, Denaro N, Merlotti A, et al. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363-371doi: 10.2147/CMAR.S115761.
Lo Nigro, C., Denaro, N., Merlotti, A., & Merlano, M. (2017). Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer management and research, 9363-371. https://doi.org/10.2147/CMAR.S115761
Lo Nigro, Cristiana, et al. "Head and neck cancer: improving outcomes with a multidisciplinary approach." Cancer management and research vol. 9 (2017): 363-371. doi: https://doi.org/10.2147/CMAR.S115761
Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017 Aug 18;9:363-371. doi: 10.2147/CMAR.S115761. eCollection 2017. PMID: 28860859; PMCID: PMC5571817.
Copy Download .nbib Format: NLM
Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system.

Cancer management and research

Zullig LL, Williams CD, Fortune-Britt AG.
PMID: 25609998
Cancer Manag Res. 2015 Jan 14;7:19-35. doi: 10.2147/CMAR.S75463. eCollection 2015.

Lung cancer (LC) and colorectal cancer (CRC) are the second- and third-most commonly diagnosed cancers in the Veterans Affairs (VA) health care system. While many studies have evaluated the treatment quality and outcomes of various aspects of VA LC...

Cite
Zullig LL, Williams CD, Fortune-Britt AG. Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system. Cancer Manag Res. 2015;7:19-35doi: 10.2147/CMAR.S75463.
Zullig, L. L., Williams, C. D., & Fortune-Britt, A. G. (2015). Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system. Cancer management and research, 719-35. https://doi.org/10.2147/CMAR.S75463
Zullig, Leah L, et al. "Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system." Cancer management and research vol. 7 (2015): 19-35. doi: https://doi.org/10.2147/CMAR.S75463
Zullig LL, Williams CD, Fortune-Britt AG. Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system. Cancer Manag Res. 2015 Jan 14;7:19-35. doi: 10.2147/CMAR.S75463. eCollection 2015. PMID: 25609998; PMCID: PMC4298347.
Copy Download .nbib Format: NLM
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

Cancer management and research

Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ.
PMID: 28293120
Cancer Manag Res. 2017 Mar 06;9:65-72. doi: 10.2147/CMAR.S124475. eCollection 2017.

BACKGROUND: Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously...

Cite
Block TS, Murphy TI, Munster PN, et al. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017;9:65-72doi: 10.2147/CMAR.S124475.
Block, T. S., Murphy, T. I., Munster, P. N., Nguyen, D. P., & Lynch, F. J. (2017). Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer management and research, 965-72. https://doi.org/10.2147/CMAR.S124475
Block, Thaddeus S, et al. "Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay." Cancer management and research vol. 9 (2017): 65-72. doi: https://doi.org/10.2147/CMAR.S124475
Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017 Mar 06;9:65-72. doi: 10.2147/CMAR.S124475. eCollection 2017. PMID: 28293120; PMCID: PMC5345989.
Copy Download .nbib Format: NLM
Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell.

Cancer management and research

Ma J, Sun X, Guo T, Su H, Chen Q, Gong Z, Qi J, Zhao X.
PMID: 29062241
Cancer Manag Res. 2017 Oct 09;9:481-493. doi: 10.2147/CMAR.S147699. eCollection 2017.

PURPOSE: This article investigates the relationship between cancer cells and stromal cells in carcinoma cell living microenvironment and elucidates the mechanism that interleukin-1 receptor antagonist (IL-1RA) blocks metastatic potential in colon cancer.METHODS: Western blot and RT-PCR assay were used...

Cite
Ma J, Sun X, Guo T, et al. Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell. Cancer Manag Res. 2017;9:481-493doi: 10.2147/CMAR.S147699.
Ma, J., Sun, X., Guo, T., Su, H., Chen, Q., Gong, Z., Qi, J., & Zhao, X. (2017). Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell. Cancer management and research, 9481-493. https://doi.org/10.2147/CMAR.S147699
Ma, Jiachi, et al. "Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell." Cancer management and research vol. 9 (2017): 481-493. doi: https://doi.org/10.2147/CMAR.S147699
Ma J, Sun X, Guo T, Su H, Chen Q, Gong Z, Qi J, Zhao X. Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell. Cancer Manag Res. 2017 Oct 09;9:481-493. doi: 10.2147/CMAR.S147699. eCollection 2017. PMID: 29062241; PMCID: PMC5640395.
Copy Download .nbib Format: NLM
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.

Cancer management and research

Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N.
PMID: 28579832
Cancer Manag Res. 2017 May 19;9:179-187. doi: 10.2147/CMAR.S129059. eCollection 2017.

BACKGROUND: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of...

Cite
Schnadig ID, Agajanian R, Dakhil C, et al. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag Res. 2017;9:179-187doi: 10.2147/CMAR.S129059.
Schnadig, I. D., Agajanian, R., Dakhil, C., Gabrail, N., Vacirca, J., Taylor, C., Wilks, S., Braun, E., Mosier, M. C., Geller, R. B., Schwartzberg, L., & Vogelzang, N. (2017). APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer management and research, 9179-187. https://doi.org/10.2147/CMAR.S129059
Schnadig, Ian D, et al. "APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial." Cancer management and research vol. 9 (2017): 179-187. doi: https://doi.org/10.2147/CMAR.S129059
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag Res. 2017 May 19;9:179-187. doi: 10.2147/CMAR.S129059. eCollection 2017. PMID: 28579832; PMCID: PMC5446958.
Copy Download .nbib Format: NLM
Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab.

Cancer management and research

Sorscher S.
PMID: 24376362
Cancer Manag Res. 2013 Dec 11;9:1-3. doi: 10.2147/CMAR.S55091. eCollection 2013.

Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and responding radiographically and biochemically to...

Cite
Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res. 2013;9:1-3doi: 10.2147/CMAR.S55091.
Sorscher, S. (2013). Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer management and research, 91-3. https://doi.org/10.2147/CMAR.S55091
Sorscher, Steven. "Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab." Cancer management and research vol. 9 (2013): 1-3. doi: https://doi.org/10.2147/CMAR.S55091
Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res. 2013 Dec 11;9:1-3. doi: 10.2147/CMAR.S55091. eCollection 2013. PMID: 24376362; PMCID: PMC3864990.
Copy Download .nbib Format: NLM
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

Cancer management and research

Greasley R, Khabazhaitajer M, Rosario DJ.
PMID: 26109877
Cancer Manag Res. 2015 Jun 12;7:153-64. doi: 10.2147/CMAR.S50585. eCollection 2015.

Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths...

Cite
Greasley R, Khabazhaitajer M, Rosario DJ. A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res. 2015;7:153-64doi: 10.2147/CMAR.S50585.
Greasley, R., Khabazhaitajer, M., & Rosario, D. J. (2015). A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer management and research, 7153-64. https://doi.org/10.2147/CMAR.S50585
Greasley, Rosa, et al. "A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer." Cancer management and research vol. 7 (2015): 153-64. doi: https://doi.org/10.2147/CMAR.S50585
Greasley R, Khabazhaitajer M, Rosario DJ. A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res. 2015 Jun 12;7:153-64. doi: 10.2147/CMAR.S50585. eCollection 2015. PMID: 26109877; PMCID: PMC4472073.
Copy Download .nbib Format: NLM
New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

Cancer management and research

Reimer P.
PMID: 26082661
Cancer Manag Res. 2015 Jun 03;7:145-51. doi: 10.2147/CMAR.S85351. eCollection 2015.

Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception of anaplastic lymphoma kinase expressing anaplastic large cell lymphoma, share a poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to...

Cite
Reimer P. New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res. 2015;7:145-51doi: 10.2147/CMAR.S85351.
Reimer, P. (2015). New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer management and research, 7145-51. https://doi.org/10.2147/CMAR.S85351
Reimer, Peter. "New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat." Cancer management and research vol. 7 (2015): 145-51. doi: https://doi.org/10.2147/CMAR.S85351
Reimer P. New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res. 2015 Jun 03;7:145-51. doi: 10.2147/CMAR.S85351. eCollection 2015. PMID: 26082661; PMCID: PMC4461120.
Copy Download .nbib Format: NLM
Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report.

Cancer management and research

Tang R, Kain T, Herman J, Seery T.
PMID: 26640390
Cancer Manag Res. 2015 Nov 19;7:357-60. doi: 10.2147/CMAR.S91547. eCollection 2015.

Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer. Since this time, however, few case reports outlining real-world usage have been published...

Cite
Tang R, Kain T, Herman J, et al. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res. 2015;7:357-60doi: 10.2147/CMAR.S91547.
Tang, R., Kain, T., Herman, J., & Seery, T. (2015). Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer management and research, 7357-60. https://doi.org/10.2147/CMAR.S91547
Tang, Ronald, et al. "Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report." Cancer management and research vol. 7 (2015): 357-60. doi: https://doi.org/10.2147/CMAR.S91547
Tang R, Kain T, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res. 2015 Nov 19;7:357-60. doi: 10.2147/CMAR.S91547. eCollection 2015. PMID: 26640390; PMCID: PMC4657800.
Copy Download .nbib Format: NLM
Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?.

Cancer management and research

Sabater S, Andres I, Lopez-Honrubia V, Berenguer R, Sevillano M, Jimenez-Jimenez E, Rovirosa A, Arenas M.
PMID: 28848362
Cancer Manag Res. 2017 Aug 09;9:351-362. doi: 10.2147/CMAR.S119125. eCollection 2017.

Endometrial cancer (EC) is one of the most common gynecological cancers among women in the developed countries. Vaginal cuff is the main location of relapses after a curative surgical procedure and postoperative radiation therapy have proven to diminish it....

Cite
Sabater S, Andres I, Lopez-Honrubia V, et al. Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?. Cancer Manag Res. 2017;9:351-362doi: 10.2147/CMAR.S119125.
Sabater, S., Andres, I., Lopez-Honrubia, V., Berenguer, R., Sevillano, M., Jimenez-Jimenez, E., Rovirosa, A., & Arenas, M. (2017). Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?. Cancer management and research, 9351-362. https://doi.org/10.2147/CMAR.S119125
Sabater, Sebastià, et al. "Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?." Cancer management and research vol. 9 (2017): 351-362. doi: https://doi.org/10.2147/CMAR.S119125
Sabater S, Andres I, Lopez-Honrubia V, Berenguer R, Sevillano M, Jimenez-Jimenez E, Rovirosa A, Arenas M. Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?. Cancer Manag Res. 2017 Aug 09;9:351-362. doi: 10.2147/CMAR.S119125. eCollection 2017. PMID: 28848362; PMCID: PMC5557121.
Copy Download .nbib Format: NLM
The clinical development of obinutuzumab for the treatment of follicular lymphoma.

Cancer management and research

Ma B, Ujjani C.
PMID: 28435325
Cancer Manag Res. 2017 Apr 10;9:103-113. doi: 10.2147/CMAR.S114526. eCollection 2017.

Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG

Cite
Ma B, Ujjani C. The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Manag Res. 2017;9:103-113doi: 10.2147/CMAR.S114526.
Ma, B., & Ujjani, C. (2017). The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer management and research, 9103-113. https://doi.org/10.2147/CMAR.S114526
Ma, Barbara, and Ujjani, Chaitra. "The clinical development of obinutuzumab for the treatment of follicular lymphoma." Cancer management and research vol. 9 (2017): 103-113. doi: https://doi.org/10.2147/CMAR.S114526
Ma B, Ujjani C. The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Manag Res. 2017 Apr 10;9:103-113. doi: 10.2147/CMAR.S114526. eCollection 2017. PMID: 28435325; PMCID: PMC5391868.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4193 entries